Safety Pharmacology CROs for Non-human Primate Studies
Showing 9 CROs. Order rotates daily so no lab is permanently listed first.
Korea Institute of Toxicology (KIT)
Government-funded Korean research institute providing GLP nonclinical safety studies, including inhalation toxicology, safety pharmacology and reproductive toxicity.
K-Prime Research (BTT Group)
Korean nonhuman primate CRO in the Biotoxtech group with GLP repeat-dose toxicity and cardiovascular safety pharmacology in NHPs, plus NHP inhalation studies.
Biotoxtech
Korean non-clinical CRO offering IND and NDA-enabling GLP toxicology, including general, reproductive and genetic toxicity, carcinogenicity and safety pharmacology, with NHP capacity through its group companies.
SAFE Pharma (Beijing Saifu)
Beijing-based preclinical CRO focused on GLP safety evaluation, with branches across China and support for biologics, nucleic acid and cell and gene therapies.
LPT Laboratory of Pharmacology and Toxicology
Independent German preclinical CRO conducting GLP toxicology, reproductive toxicology, carcinogenicity and safety pharmacology studies across rodent and non-rodent species.
InnoStar
Shanghai-based nonclinical CRO with GLP safety evaluation, pharmacology, DMPK, bioanalysis and biomarker services for small molecules, biologics and cell and gene therapies, operating several sites in China.
Shin Nippon Biomedical Laboratories (SNBL)
Long-established Japanese CRO with large GLP nonclinical safety facilities and deep nonhuman primate experience, supporting toxicology, safety pharmacology and pharmacokinetics.
CorDynamics
Specialty CRO focused on cardiovascular safety pharmacology and cardiovascular toxicology, including telemetry and hemodynamic studies in non-rodent species.